PeptiDex
Peptide Research Index
Research-backed
Peptide Research Index
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
⚠️ Educational only · Not medical advice · Consult a doctor · Most peptides are research-only / not FDA-approved for human use
Also: Elamipretide, Bendavia, MTP-131
âš¡Mitochondrial PeptideMitochondrial protection. Selectively concentrates in the inner mitochondrial membrane where it stabilizes cardiolipin for efficient electron transport chain function.
Szeto (Br. J. Pharmacol.): Comprehensive review of elamipretide mechanism and clinical trial results in heart failure, mitochondrial myopathy, and ischemia-reperfusion injury.
moderateBirk et al. (Pharmaceuticals): Detailed mechanism review showing elamipretide binds cardiolipin, stabilizes mitochondrial cristae, reduces ROS, and improves oxidative phosphorylation.
preclinicalStudy demonstrating elamipretide can reverse age-associated post-translational heart protein modifications, restoring mitochondrial function in aged cardiac tissue.
preclinicalSS-31 improves LPS-induced mitochondrial dysfunction, oxidative stress, and memory impairment in mice via BDNF signaling regulation.
preclinicalTreatment improves ADP sensitivity in aged mitochondria by increasing ANT uptake, rescuing skeletal muscle force and cardiac systolic function.
preclinicalWell-tolerated in multiple Phase 2/3 trials. Granted Fast Track and Orphan Drug designations by FDA.
⚠️ For educational purposes only. Not medical advice. Consult a healthcare professional before using any peptide.
Clinical trial doses: 4-40mg SubQ daily. Higher doses for cardiac indications.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Week 1
Improved mitochondrial efficiency; reduced exercise-induced oxidative stress
Weeks 2-4
Improved exercise capacity and recovery; reduced fatigue
Month 2-3
Cardioprotective adaptations; improved VO2 markers in clinical trials
Long-term
Sustained mitochondrial protection; FDA Fast Track designation for cardiac indications
| Side Effect | Incidence | Severity |
|---|---|---|
Well-tolerated in Phase 2/3 trials | No serious adverse events reported | mild |
Injection site reaction | ~5% of users | mild |
Incidence rates sourced from published clinical trial data where available; otherwise based on community research observations.
Improve metabolic health, insulin sensitivity, and cellular energy production
Weekly Peptide Research
New studies · vendor alerts · protocol tips
No spam. Unsubscribe anytime. Research use only.